Pulmonx Corp
Close on Oct 19, 2026
- Market cap
- $74.32M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 26, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 29, 2026 | During market hours | $22.80M | $-0.24 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 29, 2026 | During market hours | $20.60M | $-0.33 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 4, 2026 | During market hours | $22.60M | $-0.25 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 27, 2025 | During market hours | $21.50M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 30, 2025 | During market hours | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 30, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 19, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 31, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 1, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 21, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Jul 29, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| gross margin | full year 2026 | 76% | Raised |
| total operating expenses | full year 2026 | $109.00M to $111.00M | Raised |
| revenue | full year 2026 | $90.00M to $92.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Pulmonx filed with the SEC
Pulmonx Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pulmonx Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pulmonx Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue;
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Pulmonx Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pulmonx Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pulmonx Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pulmonx Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pulmonx Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Pulmonx Reports Record Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pulmonx Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Pulmonx Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K